SOPHHealthcare · Health Information ServicesSOPH Stock Forecast: SOPHiA GENETICS SA Price Predictions for 2026-2027
The 5 Wall Street analysts covering SOPHiA GENETICS SA hold a median 12-month price target of $8.5 — +49.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 1 Aug 2026 — in the lower half.
SOPH stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores SOPHiA GENETICS SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (90): The shares have been drifting up relative to others.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own SOPHiA GENETICS SA — and when they’d sell — is the membership.
SOPH stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SOPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +49.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | HC Wainwright & Co. | Initiates | Buy | $12 |
| 15 June 2026 | BTIG | Reiterates | Buy | — |
| 15 June 2026 | BTIG | Reiterates | Buy | $8.00 |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
| 15 Apr 2026 | BTIG | Maintains | Buy | — |
| 26 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 10 Nov 2025 | BTIG | Maintains | Buy | — |
| 18 Dec 2024 | Craig-Hallum | Initiates | Buy | — |
| 7 Aug 2024 | RBC Capital | Maintains | Outperform | — |
| 27 June 2024 | Guggenheim | Initiates | Buy | — |
| 6 Mar 2024 | BTIG | Maintains | Buy | — |
| 6 Mar 2024 | RBC Capital | Reiterates | Outperform | — |
| 12 Jan 2024 | RBC Capital | Reiterates | Outperform | — |
| 29 Nov 2023 | RBC Capital | Initiates | Outperform | — |
| 10 May 2023 | Credit Suisse | Maintains | Neutral | — |
| 10 May 2023 | Morgan Stanley | Maintains | Overweight | — |
| 8 Mar 2023 | Morgan Stanley | Maintains | Overweight | — |
| 3 Jan 2023 | BTIG | Initiates | Buy | — |
| 23 Nov 2022 | Credit Suisse | Initiates | Neutral | — |
| 9 Nov 2022 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SOPH analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
SOPHiA GENETICS SA (SOPH) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −4.8×
- Price / sales
- 5.9×
- Price / book
- 8.9×
- EV / EBITDA
- −5.7×
Cheaper than 89% of US stocks
Cheaper than 22% of US stocks
Cheaper than 11% of US stocks
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- 22.0%
- Earnings growth (YoY)
- 22.0%
- Gross margin
- 68.0%
- Operating margin
- −79.7%
- Net margin
- −99.7%
Higher than 74% of US stocks
Higher than 63% of US stocks
Higher than 82% of US stocks
Higher than 15% of US stocks
Higher than 6% of US stocks
- Return on equity
- −123.3%
- Return on assets
- −29.7%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SOPH vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SOPH appears on the weeks it earns a place.
Frequently asked questions about SOPH stock
What is the SOPH stock price forecast for 2026-2027?
The 5 Wall Street analysts covering SOPHiA GENETICS SA have a median 12-month price target of $8.5, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SOPH stock a buy right now?
Of the 5 analysts covering SOPHiA GENETICS SA, 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SOPHiA GENETICS SA 46 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SOPH?
As at 1 Aug 2026, SOPHiA GENETICS SA ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).
Will SOPH stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +49.4% from the last close, and Ticker Nerd's factor model ranks SOPHiA GENETICS SA 46 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SOPH stock forecast for 2030?
No analyst covering SOPHiA GENETICS SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.
How has SOPH stock performed over the past year?
SOPHiA GENETICS SA returned +80.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does SOPHiA GENETICS SA do?
SOPHiA GENETICS SA is a healthcare technology company specializing in AI-powered, cloud-native software for data-driven medicine. Headquartered in Rolle, Switzerland and founded in 2011, the company focuses on enabling hospitals, laboratories, and biopharma institutions to analyze complex health data, particularly in oncology and rare genetic disorders.
About SOPHiA GENETICS SA.
SOPHiA GENETICS SA is a healthcare technology company specializing in AI-powered, cloud-native software for data-driven medicine. Headquartered in Rolle, Switzerland and founded in 2011, the company focuses on enabling hospitals, laboratories, and biopharma institutions to analyze complex health data, particularly in oncology and rare genetic disorders. Its core offering is the SOPHiA DDM Platform, a consumption-based Software-as-a-Service solution that standardizes and interprets multimodal data, including genomic, radiomic, clinical, biological, and digital pathology information, to generate actionable insights for patient care and research. SOPHiA GENETICS supports a broad global customer network, providing applications across cancer, inherited and rare diseases, infectious diseases, cardiology, neurology, and other specialties. The company’s technology is used both in clinical workflows and by biopharma partners for drug discovery and development, positioning SOPHiA GENETICS as a key provider of medical software and technology services in precision medicine and advanced diagnostics.
CEO Mr. Ross Jordan Muken B.Sc. · 415 employees · Switzerland · https://www.sophiagenetics.com